U.S. Court in Texas Won’t Enjoin FDA Removal of Semaglutide from Shortage List
- April 30, 2025
The U.S. District Court for Northern District of Texas declined to enjoin the Food and Drug Administration (FDA) from taking enforcement action against outsourcing facilities that compound copies of Novo Nordisk’s Ozempic and Wegovy while a challenge to the agency’s decision to remove semaglutide, the active ingredient in the diabetes and weight loss medications, from its drug shortage list is pending.
ARTICLE TAGS
You must be logged in to access this content.